NASDAQ: SIONSionna Therapeutics Inc Stock
$35.92-0.13 (-0.36%)
Updated Jun 12, 2026
SION Price
$35.92
Fair Value Price
$1.25
Market Cap
$1.62B
52 Week Low
$13.51
52 Week High
$48.45
P/E
-18.71x
P/B
5.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$85.57M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$72M
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SION Overview
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SION's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SION
Ranked#321 of 463
Ranked#321 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important SION news, forecast changes, insider trades & much more!
SION News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SION scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SION ($35.92) is overvalued by 2,783.92% relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SION ($35.92) is not significantly undervalued (2,783.92%) relative to our estimate of its Fair Value price of $1.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SION is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SION due diligence checks available for Premium users.
Valuation
SION fair value
Fair Value of SION stock based on Discounted Cash Flow (DCF)
Price
$35.92
Fair Value
$1.25
Overvalued by
2,783.92%
SION ($35.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SION ($35.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SION is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SION price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.71x
Industry
16.53x
Market
14.15x
SION price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.63x
Industry
4.85x
SION is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SION's financial health
Profit margin
Revenue
$0.0
Net Income
-$26.8M
Profit Margin
0%
SION's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$305.0M
Liabilities
$16.8M
Debt to equity
0.06
SION's short-term assets ($220.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SION's short-term assets ($220.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SION's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.8M
Investing
$24.8M
Financing
$1.9M
SION's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SION vs Biotech Stocks
Sionna Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.